Results 241 to 250 of about 126,758 (293)

Plasma Elastase Screening in Hematological Disease Reveals Its Potential as a Diagnostic and Prognostic Biomarker in Hematological Malignancies

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction Neutrophil‐extracellular traps are net‐like material released by triggered neutrophils and composed of decondensed chromatin linked to nuclear proteins. Elastase, one of the fourth most represented neutrophil‐specific serine proteases stored in azurophil granules of naïve neutrophils, exerts various actions, including degradation ...
Pasqualina Scala, Anna Maria Della Corte, Angela Bertolini, Marisa Gorrese, Francesca Picone, Bianca Serio, Danilo De Novellis, Laura Mettivier, Luca Pezzullo, Maria Carmen Martorelli, Denise Morini, Matteo D'Addona, Bianca Cuffa, Carmine Selleri, Valentina Giudice   +14 more
wiley   +1 more source

Single-dose rituximab as induction therapy in adult IgA vasculitis with rapidly progressive glomerulonephritis: a case report with peripheral blood CD19⁺ B-cell monitoring. [PDF]

CEN Case Rep
Kyoda N, Ago R, Masuzawa N, Yanamoto M, Aizawa M, Masaki T.   +5 more
europepmc   +1 more source

A Rare Case of Concurrent Chronic Lymphocytic Leukemia and Therapy-Unrelated Acute Myeloid Leukemia That Evolved From Myelodysplastic Neoplasm. [PDF]

Cureus
Bansil S, Lai SY, Lo AE, Dietz R, Reed JP.   +4 more
europepmc   +1 more source

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research. [PDF]

Curr Treat Options Oncol
Alipourfard I, Shafaghat Z, Saharkhiz S, Farani MR, Bakhtiyari S.   +4 more
europepmc   +1 more source

Case Report: Compromised response of memory-formed bystander T cells after CD19 CAR-T cell therapy following CD20 bispecific antibody therapy. [PDF]

Front Immunol
Masuda Y, Kato J, Konishi T, Honda T, Maruta M, Kawasaki N, Matsumoto M, Oka K, Mori K, Nabe S, Miyazaki Y, Matsubara E, Urata S, Kinnami S, Doi Y, Takasuka Y, Yamanouchi J, Ochi T, Takenaka K.   +18 more
europepmc   +1 more source

Breakthroughs and challenges of CAR-T cell therapy in treating hematologic malignancies of the central nervous system. [PDF]

Blood Sci
Li X, Da H, Zhao J, Yan Y, Wei J, Tian W.   +5 more
europepmc   +1 more source

Combined blinatumomab and CD19 CAR T-cell therapy for newly diagnosed adult Ph⁻ BCP-ALL: A retrospective study. [PDF]

Ann Hematol
Jiang B, Zhu Y, Jiang Y, Huang J, Liu Y, Tang M, Lu J, Chen S.   +7 more
europepmc   +1 more source

An Unusual Case of Classic Hodgkin Lymphoma With Strong Expression of B‐Cell Markers

International Journal of Laboratory Hematology, EarlyView.
Christopher Liwski, Sorin Selegean, Allam Shawwa, David M. Conrad   +3 more
wiley   +1 more source

Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins

Molecular Pharmaceutics, 2019
CD19-targeted chimeric antigen receptor (CAR) T-cells (CAR19s) show remarkable efficacy in the treatment of relapsed/refractory acute lymphocytic leukemia and Non-Hodgkin's lymphoma. However, the use of CAR T-cell therapy against CD19-negative hematological cancers and solid tumors has been challenging.
Justin R Klesmith, Lihe Su, Christine Ambrose   +2 more
exaly   +4 more sources

CD19 Chimeric Antigen Receptor-Exosome Targets CD19 Positive B-lineage Acute Lymphocytic Leukemia and Induces Cytotoxicity

Cancers, 2021
CAR-T cell therapy is not without some clinical adverse effects, namely cytokine storms, due to a massive release of cytokines when CAR-T cells multiply in the body.
Shabirul Haque, Haque Shabirul
exaly   +2 more sources